Brand: YC
Model: Skype: tom131393
Price: USD 1 / g
Min. Order: 10 g g
PU-H71 CAS:873436-91-0

Product Name: PU-H71
CAS: 873436-91-0
MF: C18H21IN6O2S
MW: 512.36781
Product Categories: API
Appearance : White powders
Purity : 99%
Package : 1kg/foil bag
density : 1.84
Usage: PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. PU-H71 is a potent Hsp90 inhibitor (IC50 = 50 nM). Hsp90 plays a critical role in modulating the activity of many cell signaling proteins and are an attractive target for anti-cancer therapeutics. Stu dies indicate that Hsp90 inhibitors may serve as potential anti-Parkinson disease.

In vitro :
PU-H71 (1 μM) potently suppresses the growth of triple-negative breast cancers (TNBC) cell lines MDA-MB-468, MDA-MB-231, and HCC-1806 with IC50 of 65, 140 and 87 nM, respectively. PU-H71 (1 μM) kills 80%, 65%, and 80% of the initial population of MDA-MB-468, MDA-MB-231, and HCC-1806 cells, respectively. PU-H71 (0.25-1 μM) induces a dose-dependent degradation or inactivation of tumor driving molecules, including EGFR, IGF1R, HER3, c-Kit, Raf-1and Akt. Treatment for 24 h with 1 μM PU-H71, augments the percent of cells in G2-M phase of MDA-MB-468 to 69%, mediated by reduction in CDK1 and Chk1 expression. PU-H71 induces apoptosis in TNBC in part by inactivation and downregulation of Akt and Bcl-xL. PU-H71 leads to a proteasome-mediated reduction in IRAK-1 and TBK1 levels, resulting in approximately 84% and 90% reduction in NF-κB activity in MDA-MB-231 cells treated with 0.5 and 1μM PU-H71, respectively. PU-H71 markedly contains MDA-MB-231 cell invasion, with 90% suppression at 1 μM. PU-H71 (2.5 μM) generates endoplasmic reticulum (ER) stress and activated the Unfolded Protein Response (UPR) as evidenced by XBP1 mRNA splicing (2.3-fold) and up-regulation of Grp94 (3.7-fold), Grp78 (4.9-fold), and CHOP (48-fold) protein expression and ATF4 (1.8-fold) mRNA expression. PU-H71 (1 μM) induces the mitochondrial pathway of apoptosis in HeLa cells, mediated by caspase but not calpain activation. In response to PU-H71-induced ER stress, apoptosis is triggered in melanoma, cervix, colon, liver and lung cancer cells, but not in normal human fibroblasts. PU-H71 is able to induce apoptosis overcoming the resistance conferred by Bcl-2. PU-H71 (30 n M) significantly reduces NOS2 activity (60% reduction) and expression in LI (1 μg/mL LPS and 5 ng/mL IFN γ)-stimulated astrocytes via inhibiting NF-κB element activation. PU-H71 displays similar effects on microglial cells as on astrocytes, with 50 nM PU-H71 needed to significantly reduce the LPS dependent nitrite release.

In vivo :
PU-H71 administered at 75 mg/kg a.d. in the MDA-MB-231 model, induces a 100% complete response, and tumors are reduced to scar tissue after 37 days of treatment, accompanied with reduction in many proliferative and anti-apoptotic molecules, namely an 80%, 95%, 99%, 80%, and 65% decrease in EGFR, HER3, Raf-1, Akt, and p-Akt, respectively. PU-H71 (75 mg/kg, 3 times per week) induces a 96% inhibition of tumor growth, accompanied by an 60% reduction in tumor cell proliferation, an 85% decline in activated Akt associated with survival and high invasive potential, and a 6-fold increase in apoptosis.

Related HSP (e.g. HSP90) Products :
KNK437 CAS: 218924-25-5
VER155008 CAS: 1134156-31-2
FRAX597 CAS: 1286739-19-2
17-AAG (Tanespimycin) CAS: 75747-14-7
Luminespib (AUY-922, NVP-AUY922) CAS : 747412-49-3
Ganetespib (STA-9090) CAS: 888216-25-9
17-DMAG (Alvespimycin) HCl CAS: 467214-21-7
Geldanamycin CAS: 30562-34-6
Alvespimycin CAS: 467214-20-6
HSP990 (NVP-HSP990) CAS: 934343-74-5
Elesclomol (STA-4783) CAS: 488832-69-5
Crizotinib (PF-02341066) CAS: 877399-52-5
Olaparib (AZD2281, Ku-0059436) CAS: 763113-22-0
BIIB021 CAS: 848695-25-0
Cilomilast CAS: 153259-65-5
INK 128 (MLN0128) CAS: 1224844-38-5